ClinPhone Opens New Paris Office
ClinPhone strengthens its presence in Europe with the opening of a new Paris office.
Nottingham UK-May 15, 2008-ClinPhone (www.clinphone.com), the world’s largest Clinical Technology Organization (CTO), announced the opening of its new Paris office, further increasing its presence in this geographic region. The office opening was marked by an opening ceremony at Le Train Bleu, Place Louis Armand, Paris. The invitation-only event was attended by ClinPhone staff, clients and partners.
ClinPhone already has a number of large pharmaceutical clients based in France that have benefited from using ClinPhone’s clinical technologies. This new office will provide both its current and new customers within this region with a local point of contact.
Damien Tremolet, director of operations at ClinPhone, will lead the new office, which is centrally located in the business center of the Gare de Lyon station in Paris, France. He will be supported by Jacques Rudelle, an associate director of business development at ClinPhone.
A clear objective for ClinPhone has been to seek market opportunities and growth areas in Europe to specifically establish a first line physical presence. Having a local presence enables ClinPhone to provide increased face-to-face contact, trial consultations and expert advice in local languages.
“Customer service is a vital part of any successful business and ClinPhone prides itself on providing the best possible support to all of its clients regardless of location,” comments Steve Kent, chief executive officer, ClinPhone. “The opening of this new office is testament to our continued unwavering commitment and we are very excited about our expansion.”
ClinPhone has a comprehensive portfolio of clinical technology solutions, including its newly-launched DataLabs by ClinPhone (EDC) and ClinPhone Randomization and Trial Supply Management (IVR/IWR) integrated solution, electronic data capture (EDC), randomization, trial supply management, drug accountability, electronic patient reported outcomes (ePRO), clinical trial management systems (CTMS) and integration solutions. ClinPhone is the first company of its kind to offer such a comprehensive suite of software and services to the biopharmaceutical industry.
ClinPhone provides a range of clinical technology solutions to many of the world’s leading pharmaceutical and biotechnology companies. The company is the largest and most accomplished Clinical Technology Organization (CTO) in the industry, with experience in more than 2000 trials.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
